The content on this site is intended for healthcare professionals only
OncoAlert and ecancer weekly round up for October 11th - October 16, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
18 Oct 2021
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or car...
Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA
14 Sep 2021
Should every transplant eligible NDMM patient receive a transplant?
Prof Morie Gertz - Mayo Clinic, Rochester, USA
14 Sep 2021
Vaccinations in myeloma patients including for COVID-19
Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria
31 Aug 2021
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax fo...
Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, N...
10 Jun 2021
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than l...
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
13 Apr 2021
Real-world evidence of the use of carfilzomib among multiple myeloma patients ac...
Prof Evangelos Terpos - University of Athens, Athens, Greece
22 Dec 2020
Real-world evidence of the use of carfilzomib to refractory to lenalidomide pati...
Prof Evangelos Terpos - University of Athens, Athens, Greece
22 Dec 2020
Real world management of multiple myeloma patients
Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
8 Dec 2020
Updates in geriatric medical oncology from SIOG meeting
Dr Enrique Soto - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zu...
28 Oct 2020
Management of infection risk to myeloma patients during the COVID pandemic
Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology, Vienn...
1 Oct 2020
Lenalidomide combination for multiple myeloma
Prof Xavier Leleu - Hôpital La Mileterie CHU, Poitiers, France
1 Oct 2020